Lexaria Bioscience (NASDAQ: LEXXW- CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive with news the company is planning for a very busy 2021 with a number of research and development initiatives.
Bunka telling Proactive they are planning research on DehydraTECH-CBD For Hypertension and they are also looking at DehydraTECH with Antivirals for COVID-19.